FDA Category 2 and withdrawn nominations
This is a note about documents, not a complete legal opinion.
What the opened sources say
Section titled “What the opened sources say”- FDA says bulk substances nominated for the 503A or 503B bulks lists can be placed in Category 2 under interim policies when FDA identifies potential significant safety risks.
- The Category 2 table opened for this draft includes, among other substances, GHRP-2 (injectable and nasal, 503B, added 29 September 2023), GHRP-6 (503B, same date), and ipamorelin acetate (503B, same date). The table also lists substances that are not peptides. This page does not copy every row.
- A second table, “Bulk drug substances nominated but withdrawn,” says those substances were previously in Category 2 and were withdrawn by the nominators. Entries relevant to other pages on this wiki include BPC-157, CJC-1295, injectable GHK-Cu, melanotan II, MOTs-C, and thymosin beta-4 fragment (LKKTETQ), also called TB-500.
- Withdrawal by a nominator is not, on this page, rewritten as a statement that compounding is lawful or unlawful. Read the FDA page and the statute before relying on a legal conclusion.
Not stated here
Section titled “Not stated here”Dates of withdrawal are not stated because the opened page did not print a withdrawal date for those rows.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Regulatory status: U.S. FDA interim categories for bulk substances nominated under sections 503A or 503B. Not a full statement of compounding law.
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (primary, accessed 2026-11-20)
Referenced by
- BPC-157
- CJC-1295
- GHK-Cu
- Ipamorelin
- Melanotan II
- MOTS-c
- PCAC meeting, 23–24 July 2026
- Regulation
- Research-use labeling in the United States
- TB-500
A link from another wiki page is not evidence. Facts should point at the sources above.